Based on the Aethlon Medical Inc stock forecast from 1 analysts, the average analyst target price for Aethlon Medical Inc is USD 10.00 over the next 12 months. Aethlon Medical Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aethlon Medical Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Aethlon Medical Inc’s stock price was USD 1.42. Aethlon Medical Inc’s stock price has changed by -9.29% over the past week, -15.27% over the past month and -66.31% over the last year.
No recent analyst target price found for Aethlon Medical Inc
No recent average analyst rating found for Aethlon Medical Inc
Company Overview Aethlon Medical Inc
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California. Address: 11555 Sorrento Valley Road, San Diego, CA, United States, 92121 Read Less
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and ...Read More
Frequently Asked Questions About Aethlon Medical Inc (AEMD) Stock
Based on ratings from 1 analysts Aethlon Medical Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on AEMD's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AEMD is USD 10.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 10.
AEMD stock's Price/Earning ratio is 1.96.
Our analysis grades AEMD stock's Price / Earning ratio at C-. This means that AEMD stock's Price/Earning ratio is above 28% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this AEMD may be undervalued for its sector.
The last closing price of AEMD's stock was USD 1.42.
The most recent market capitalization for AEMD is USD 3.72M.
Based on targets from 1 analysts, the average taret price for AEMD is projected at USD 10.00 over the next 12 months.
This means that AEMD's stock price may go up by +606.71% over the next 12 months.
We can't find any ETFs which contains Aethlon Medical Inc's stock.
As per our most recent records Aethlon Medical Inc has 15 Employees.
Aethlon Medical Inc's registered address is 11555 Sorrento Valley Road, San Diego, CA, United States, 92121.
You can get more information about it from Aethlon Medical Inc's website at http://www.amundi.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AEMD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
